Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Head Verma Unveils Favorable Coding Changes For Medtech, Pharma At MDMA Meeting

Executive Summary

The US Centers for Medicare and Medicaid Services will allow device manufacturers to submit requests for HCPCS codes for emerging technology on a semi-annual basis, and drug-makers will be allowed to submit quarterly, CMS chief Seema Verma told an MDMA audience at the industry advocacy group's annual meeting on 2 May.

You may also be interested in...



‘Disease Doesn’t Respect Silos’: Sharpless Sets Flexibility As Priority

Acting US FDA Commissioner Ned Sharpless described his vision for an efficient, adaptable agency on 2 May at the Food & Drug Law Institute’s annual conference in Washington, DC.

Breakthrough Devices To Get Special US Medicare Reimbursement Under CMS Proposal

The US Centers for Medicare and Medicaid Services plans to automatically allow reimbursement and up to 65% new technology add-on payments for US FDA-approved, -cleared or de novo devices in the agency's Breakthrough Devices Program. Industry groups, including the Medical Device Manufacturers Association and AdvaMed, have been pushing CMS for such coverage for several years.

'Full-Speed Ahead,' Says Acting US FDA Chief Sharpless

In his first speech to agency staff, US FDA acting Commissioner Ned Sharpless says the agency will continue working on issues such as the Medical Device Safety Action Plan, the precertification program and the National Evaluation System for health Technology (NEST). He also says he's not approaching the post like a temporary caretaker.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT125042

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel